STRUMBERG DIRK,SCHULTHEIS BEATE,EBERT MATTHIAS P,SIVEKE JENS,KERKHOFF ANDREA,HOFHEINZ RALF,BEHRINGER DIRK M,SCHMIDT WOLFGANG E,GOKER ERDEM,DE DOSSO SARA,KNEBA MICHAEL,YALCIN SUAYIB,OVERKAMP FRIEDRICH
申请号：
IN201817003007
公开号：
IN201817003007A
申请日:
2018.01.25
申请国别(地区):
IN
年份:
2018
代理人:
摘要：
The present disclosure relates to the field of immunotherapy of cancer in particular pancreatic ductal adenocarcinoma (PDAC). Means and methods for treatment of a population of PDAC patients suffering from PDAC tumours which express wild type KRAS HRAS or NRAS are disclosed. The claimed antibody is Nimotuzumab. The pancreatic cancer preferably does not contain KRAS mutations at position 12 16 61 154.
